XERS: Xeris Biopharma Holdings, Inc. Stock

by  •  • Comments Off on XERS: Xeris Biopharma Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 480.04
Enterprise Value ($M) 652.09
Book Value ($M) -28.32
Book Value / Share -0.19
Price / Book -16.95
NCAV ($M) -186.63
NCAV / Share -1.25
Price / NCAV -2.57

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.20
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.29
Current Ratio 1.79

Balance Sheet (mrq) ($M)
Current Assets 162.80
Assets 321.10
Liabilities 349.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Stonepine Capital Management, LLC 4.30 -46.97
02-13 13G Vanguard Group Inc 5.13
01-26 13G BlackRock, Inc. 7.20 494.44

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPOR
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-17 206,601 829,333 24.91
2025-01-16 194,867 913,608 21.33
2025-01-15 232,186 1,239,814 18.73
2025-01-14 260,855 1,034,037 25.23
2025-01-13 369,714 1,764,011 20.96

(click for more detail)

Similar Companies
VTYX – Ventyx Biosciences, Inc. VYGR – Voyager Therapeutics, Inc.
XBIT – XBiotech Inc. XLO – Xilio Therapeutics, Inc.
YMAB – Y-mAbs Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io